Myomo Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
21.4%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$45.3Mnext fiscal year
FY EPS (est.)
-$0.30next fiscal year
Monitoring Framework
Key Performance Indicators
MyoPro Units Recognized as Revenue Quarterly172
Average Selling Price (ASP) of MyoPro Quarterly58.8K
Reimbursement Pipeline Patients Annually1.5K
Backlog Patients Quarterly226.0
Percentage of Revenue from Recurring Patient Sources Quarterly49.0
Watch Items
- Medicare Advantage Plan Denials and AppealsTrigger: Increase in denial rates or delays in Administrative Law Judge (ALJ) hearing schedulesAction: Escalate direct engagement with payer medical directors and file formal complaints with CMS.
- Customer Acquisition Cost (CAC) and Cost per Pipeline AddTrigger: Cost per pipeline add exceeding $3,000Action: Re-evaluate digital marketing agency performance and accelerate shift to lower-cost direct billing referrals.
Research as of 20 Jun 2026